Adverum Biotechnologies, Inc. (ADVM) AI Stock Price Forecast & Investment Analysis
Latest Analysis Date: July 18, 2025
Adverum Biotechnologies, Inc. (ADVM) - Comprehensive Stock Analysis & Investment Research
Company Overview & Business Profile
Adverum Biotechnologies, Inc. (Stock Symbol: ADVM)
is a leading company in the Life Sciences sector
, specifically operating within the Biological Products, (No Diagnostic Substances) industry.
The organization employs approximately 174 professionals worldwide
.
The company has established itself as
an emerging investment opportunity with substantial growth potential.
Financial Performance & Key Metrics Analysis
Market Capitalization: $58 million - Classified as a
small-cap investment offering high growth potential.
Return on Equity (ROE): -44.4% -
Below-average
shareholder return efficiency, indicating areas for operational improvement.
Advanced AI Stock Prediction & Price Target Analysis
🚀 Unlock Premium AI Predictions to access our advanced machine learning forecasts for Adverum Biotechnologies, Inc. stock, including 7-day, 30-day, and 90-day price targets with confidence intervals and risk assessments.
Market Position & Competitive Advantage Analysis
Adverum Biotechnologies, Inc. strategically competes in the highly dynamic
Biological Products, (No Diagnostic Substances) marketplace,
representing an emerging small-cap investment with substantial growth potential and market disruption capabilities
.
.
Adverum Biotechnologies, Inc. Stock Price Chart and Technical Analysis
Loading chart data...
Loading Adverum Biotechnologies, Inc. interactive price chart and technical analysis...
Deep dive into Adverum Biotechnologies, Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.
Understanding Valuation Metrics
What these metrics mean: Valuation metrics help determine if Adverum Biotechnologies, Inc. stock is fairly priced compared to its earnings, assets, and market position.
How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.
For Adverum Biotechnologies, Inc.: With a P/E ratio of -1.75, the market sees the stock as potentially undervalued.
P/E Ratio-1.75x
P/B Ratio2.18x
Market Cap$58M
EPS$-3.92
Book Value/Share$1.27
FCF/Share$-1.18
Understanding Profitability Metrics
What these metrics mean: These ratios measure how efficiently Adverum Biotechnologies, Inc. converts revenue into profit and generates returns for shareholders.
How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.
For Adverum Biotechnologies, Inc.: An ROE of -44.4% indicates room for improvement in shareholder value creation.
ROE-44.4%
ROA-35.7%
ROIC-37.3%
Operating Margin-50539.2%
Net Margin-41045.6%
Understanding Financial Health Metrics
What these metrics mean: These ratios assess Adverum Biotechnologies, Inc.'s ability to meet short-term obligations and manage debt levels effectively.
How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.
For Adverum Biotechnologies, Inc.: A current ratio of 12.05 indicates strong liquidity.
Current Ratio12.05x
Quick Ratio11.66x
D/E Ratio0.35x
Financial Leverage1.44x
Interest Coverage-71.3x
Working Capital$414M
Understanding Cash Flow Metrics
What these metrics mean: Cash flow metrics reveal Adverum Biotechnologies, Inc.'s ability to generate cash from operations and fund growth initiatives.
How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.
For Adverum Biotechnologies, Inc.: Free cash flow of $-133M indicates cash challenges that need attention.
Operating Cash Flow$-114M
Free Cash Flow$-133M
Capital Spending$-18M
FCF/Sales-472.1%
CapEx/Sales201.6%
Understanding Operational Efficiency Metrics
What these metrics mean: These ratios measure how effectively Adverum Biotechnologies, Inc. uses its assets and manages working capital.
How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.
For Adverum Biotechnologies, Inc.: An asset turnover of 0.02x suggests room for improvement in asset utilization.
Asset Turnover0.02x
Receivables Turnover1.3x
Fixed Assets Turnover0.1x
Days Sales Outstanding278 days
Understanding Financial Statement Data
What these metrics mean: Key figures from Adverum Biotechnologies, Inc.'s income statement and balance sheet showing absolute financial performance.
How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.
For Adverum Biotechnologies, Inc.:
Income Statement ($ Millions)
Operating Income$-103M
Net Income$-94M
R&D Expense$68M
SG&A Expense$859M
Balance Sheet Highlights ($ Millions)
Total Current Assets$69M
Cash & Short-term Investments$67M
Total Liabilities$31M
Accounts Receivable$1M
Dividend & Shareholder Information
Shares Outstanding21M
Growth Metrics (YoY)
EPS Growth-95.8%
Adverum Biotechnologies, Inc. (ADVM) Fundamental Analysis & Insider Trading Data
(Quarterly Financial Reports)
Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Adverum Biotechnologies, Inc. stock analysis.
Loading fundamental data...
Loading Adverum Biotechnologies, Inc. comprehensive fundamental analysis and insider trading data...
Latest Adverum Biotechnologies, Inc. Stock News & Market Analysis
Breaking news, analyst reports, and market updates affecting Adverum Biotechnologies, Inc. (ADVM) stock price and investment outlook.
Based on our data, Adverum Biotechnologies insiders have about 1.9% of the stock, worth approximately US$4.0m. We prefer to see high levels of insider ownership.
REDWOOD CITY, Calif., July 10, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for ...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM GlobeNewswire Apr 25, 2025 10:12am ...
ARTEMIS Phase 3 trial enrollment exceeding expectations; driven by strong retina specialist and patient enthusiasm for a potential One And Done™ therapy for wet AMD - ARTEMIS enrollment completion ...
Adverum Biotechnologies Inc. 100 Cardinal Way Redwood City, California 94063 Phone1 650 656-9323 IndustryBiotechnology SectorHealth Care/Life Sciences Fiscal Year-end12/2025 Revenue€1M Net ...
REDWOOD CITY, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly ...
MENLO PARK, Calif., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ophthalmology and rare ...
REDWOOD CITY, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy to preserve sight for life in highly ...
Adverum Biotechnologies' stock was down by 60.2% as of 11:30 a.m. EDT. So what ADVM-022 is an experimental gene therapy for the treatment of diabetic macular edema (DME).
Adverum Biotechnologies' 174 thousand square-foot facilities will come with more than 200 new jobs when it opens in 2023. The company targets unmet medical needs in ocular and rare diseases.
Adverum Biotechnologies Inc. 100 Cardinal Way Redwood City, California 94063 Phone1 650 656-9323 IndustryBiotechnology SectorHealth Care/Life Sciences Fiscal Year-end12/2025 Revenue$1M Net Income ...
Adverum Biotechnologies, Inc. Competitors & Peer Analysis - Life Sciences Sector
Comparative analysis of Adverum Biotechnologies, Inc. against industry peers and competitors in the Life Sciences sector, featuring AI-powered forecasts and key financial metrics.
Frequently Asked Questions - Adverum Biotechnologies, Inc. Stock Forecast
How accurate are Adverum Biotechnologies, Inc. stock predictions?
Our AI model demonstrates 22% historical accuracy for ADVM predictions, based on advanced machine learning algorithms trained on over 10 years of market data.
What factors influence Adverum Biotechnologies, Inc. stock price forecasts?
Is Adverum Biotechnologies, Inc. a good investment in 2025?
Based on our AI analysis, Adverum Biotechnologies, Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.
How often are Adverum Biotechnologies, Inc. forecasts updated?
Adverum Biotechnologies, Inc. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.
Want More Advanced Adverum Biotechnologies, Inc. Analysis?
Unlock premium features including detailed price targets, risk assessments, portfolio optimization, and real-time alerts for Adverum Biotechnologies, Inc. stock.
